Betahistine alleviates benign paroxysmal positional vertigo (BPPV) through inducing production of multiple CTRP family members and activating the ERK1/2-AKT/PPARy pathway

BACKGROUND: Betahistine is a clinical medication for the treatment of benign paroxysmal positional vertigo (BPPV). Otolin, a secreted glycoprotein with a C-terminal globular domain homologous to the immune complement C1q, has been identified as a biomarker for BPPV. However, the role of complement C...

Descripción completa

Detalles Bibliográficos
Autores principales: Hui, Jing, Lei, Qi, Ji, Zhi, Zi, Dingjing
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981858/
https://www.ncbi.nlm.nih.gov/pubmed/35379352
http://dx.doi.org/10.1186/s40659-022-00385-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8981858/
https://www.ncbi.nlm.nih.gov/pubmed/35379352
http://dx.doi.org/10.1186/s40659-022-00385-3

Ejemplares similares